- 1 Identification of *Trypanosoma brucei gambiense* and *T. b. rhodesiense*
- 2 in vectors using multiplexed high-resolution melt analysis.
- 3 Gala Garrod¹, Emily R. Adams², Jessica K. Lingley¹, Isabel Saldanha¹, Stephen J. Torr¹, Lucas J.
- 4 Cunningham¹
- 5 ¹Department of Vector Biology, Liverpool School of Tropical Medicine, Liverpool, L3 5QA
- 6 ²Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool L3 5QA
- 7

9 Abstract

10 Background

- 11 Human African Trypanosomiasis (HAT) is a potentially fatal parasitic infection caused by the
- 12 trypanosome sub-species *Trypanosoma brucei gambiense* and *T. b. rhodesiense* transmitted by
- 13 tsetse flies. Currently, global HAT case numbers are reaching less than 1 case per 10,000 people in
- 14 many disease foci. As such, there is a need for simple screening tools and strategies to replace active
- 15 screening of the human population which can be maintained post-elimination for Gambian HAT and
- 16 long-term Rhodesian HAT. Here we describe the development of a novel high-resolution melt assay
- 17 for the xenomonitoring of *Trypanosoma brucei gambiense* and *T. b. rhodesiense* in tsetse.

18 Methods

- 19 Primers for T. b. rhodesiense and T. b. gambiense were designed to target species-specific single
- 20 copy genes. An additional primer set was included in the multiplex to determine if samples have
- sufficient genomic material for detecting low copy number targets. The assay was evaluated on 96
- 22 wild-caught tsetse previously identified to be positive for *T. brucei s. l.* of which two were infected
- 23 with *T. b. rhodesiense*.

24 Results

- 25 The assay was found to be highly specific with no cross-reactivity with non-target trypanosome
- species and the assay limit of detection was 10⁴ tryps/mL. HRM successfully identified three *T. b.*
- 27 *rhodesiense* positive flies and was in agreement with the reference sub-species-specific PCRs. This
- assay provides an alternative to running multiple PCRs when screening for pathogenic sub-species of
- 29 *T. brucei* s. I and produces results in ~2 hours, avoiding gel electrophoresis.

30 Conclusions

- 31 This method could provide a component of a simple and efficient method of screening large
- 32 numbers of tsetse flies in known HAT foci or in areas at risk of recrudescence or threatened by the
- 33 changing distribution of both forms of HAT.

35 Introduction

36 Human African Trypanosomiasis (HAT) is a potentially fatal disease caused subspecies of 37 Trypanosoma brucei transmitted by the bite of an infected tsetse fly (Glossina spp). HAT consists of 38 two forms of the disease, each with its own distinct parasite, vectors, disease pathology, treatment 39 and geographical distribution. Gambian HAT (gHAT), caused by Trypanosoma brucei gambiense, is a 40 largely anthroponotic disease found across central and west Africa and accounts for the large 41 majority of HAT cases (>97%) (1). GHAT can remain asymptomatic for months to years with 42 symptoms often presenting once the infection has significantly advanced. Conversely, Rhodesian 43 HAT (rHAT), caused by Trypanosoma brucei rhodesiense, is a zoonosis with occasional human 44 infection, and represents less than 3% of all HAT cases. The World Health Organisation has targeted the elimination of HAT as a public health problem by 2020, defined as less than 1 new case per 10, 45 46 000 inhabitants in at least 90% of endemic foci and fewer than 2000 cases reported globally. Due to 47 the zoonotic nature of rHAT, this WHO target is applicable to gHAT only. With gHAT on the brink of elimination and rHAT control remaining an important priority both in terms of human (2) and animal 48 49 health, it is crucial to identify any remaining active cases, foci of transmission and areas of 50 resurgence. The epidemiology of the two forms of HAT differ greatly therefore the monitoring and 51 screening strategies for each form differ accordingly. Monitoring gHAT is largely reliant on the 52 screening of the at-risk human population and treatment of cases (3). Accurate estimates of disease 53 prevalence require high rates of coverage, which can be difficult to achieve, particularly in areas 54 affected by conflict and political instability (4) and as the prevalence approaches <1 case per 10,000. 55 As a result, there has been emphasis on the development of rapid diagnostic tests (RDTs) and field-56 friendly screening tools. In comparison to gHAT, there has been little progress or investment into the 57 development of a screening tool for rHAT with current emphasis on passive case detection and 58 control of the vector population. A reliance on passive detection results in a delay in the 59 identification and treatment of infected individuals, both of which are crucial for the control of 60 disease transmission.

With declining numbers of cases, active screening programmes are no longer cost-effective (5) and
there is a need for a monitoring tool which can be maintained sustainably for rHAT and postelimination for gHAT.

Xenomonitoring, the screening of vectors for the presence of parasites, provides a potential 64 65 alternative to host sampling. This method has already been successfully utilised as a surveillance tool 66 within the Lymphatic Filariasis elimination programme (6–8). Vectors are often routinely collected as 67 part of vector control programmes and are far simpler and less costly to sample than either human 68 or animal populations. Additionally, screening vectors for infection is often less time consuming and 69 with efficient processing, can provide a view of disease transmission in real-time. Microscopy has 70 been traditionally used for vector screening due to its low cost, high specificity and ease of use in-71 field. However, the sensitivity of microscopy is highly variable and morphological identification of T. 72 *brucei gambiense* and *T. b. rhodesiense* trypanosomes is not possible.

73 The development of molecular tools has provided highly sensitive alternatives to traditional 74 screening methods. PCR is widely used for the detection of *Trypanosoma* DNA, with highly sensitive 75 assays developed for T. brucei s. I (9) which includes T. b. gambiense and T. b. rhodesiense along with 76 the animal trypanosome T. b. brucei. Successful amplification of the target indicates the presence of 77 one of the members of *T. brucei* s. *I.* but does not identify which sub-species is present. Identification 78 of T. b. gambiense and T. b. rhodesiense is reliant on the detection of specific single-copy genes for 79 each subspecies. For detection of these genes, the presence of sufficient genetic material is crucial. 80 A negative result may indicate the absence of the target species or simply that insufficient DNA is 81 present. To differentiate between these two scenarios, primers have been designed to screen for 82 other single-copy genes (10), namely a single-copy phospholipase-C (GPI-PLC) expressed by all 83 members of T. brucei s. l. (11–14). Samples found to have sufficient DNA can then be screened using 84 primers specific for T. brucei s. I. subspecies

85 High-resolution melt analysis (HRM) is a post-qPCR analysis method which can be used to detect 86 heterogeneity within nucleotide sequences. A fluorescent dye is added to the PCR reaction which 87 intercalates into double stranded DNA. Following amplification, the amplicon is heated gradually 88 causing the strands to separate. Separation of the double strands releases the incorporated dye 89 causing a drop in fluorescence. The rate of DNA strand disassociation and the temperature at which 90 it separates (Tm) is dependent on the nucleotide sequence. Different sequences will have different 91 melting temperatures which can be used as a diagnostic identifier. HRM is a closed tube process 92 resulting in a reduced risk of contamination and produces results in approximately two hours making 93 circumventing gel electrophoresis, making it a faster, more specific alternative to traditional PCR. 94 Multiplexing allows for the screening of a number of targets simultaneously, making sample 95 processing more efficient. Here, we describe the design of a multiplexed HRM assay for the 96 identification of the two sub-species of HAT: T. b. rhodesiense and T. b. gambiense and sufficient 97 DNA for single-copy gene identification. Methods 98

99 Primers were designed to produce an amplicon of 150-350 base pairs with distinct melt

100 temperatures. T. b. rhodesiense primers were derived from the sequence for the T. brucei

101 *rhodesiense* serum-resistance-associated (SRA) protein gene (accession number AF097331.1).

102 Primers for *T. b. gambiense* were previously designed and published by Radwanska *et al.* (15) and

103 target the sub-species-specific glycoprotein (TgsGP: accession number AJ277951). A third primer set

104 was designed to identify the presence of sufficient genetic material. These primers amplify a single-

105 copy phospholipase-C (GPI-PLC) gene expressed by all members of the Trypanozoon group (11–14).

106 HRM assay

HRM reactions were run in a total volume of 12.5µl consisting of 2.5µl DNA template, 6.25 µl HRM
Master Mix (Thermo-start ABgene, Rochester, New York, USA), 3.25 µl sterile DNase/RNase free
water (Sigma, ST. Louis, USA) and 400nM of all forward and reverse primers. Reactions were carried

out on a Rotor-Gene 6000 real-time PCR machine (Qiagen RGQ system). The following protocol was
followed: denaturation at 95°C for 5 minutes followed by 40 cycles and denaturation for 10 seconds
at 95°C per cycle, annealing and extension for 30 seconds at 58°C, and final extension for 30 seconds
at 72°C. The melting step ran from 75°C to 95°C with a temperature increase of 0.1°C every 2
seconds.

115 Specificity and analytical sensitivity

116 The specificity of the multiplexed assay was evaluated using DNA from a range of non-target

117 trypanosome species: Trypanosoma congolense Savannah (Gam2), T. congolense Forest (ANR3), T.

118 congolense Kilifi (WG84), T. simiae (TV008), T. godfreyi (Ken7), T. vivax (Y486), T. grayi (ANR4) and T.

119 *brucei brucei* (M249). The analytical sensitivity of the assay was assessed using a ten-fold dilution

120 series of target species DNA. Sub-species-specific PCRs were run alongside for direct comparison of

121 sensitivities (10,15).

122 Screening of field samples

123 A subsample of 96 wild-caught tsetse (Glossina swynnertoni, G. pallidipes), previously shown to be T. 124 brucei s. I. positive were screened individually for infection using HRM. The flies were from a 125 collection of 5986 tsetse originally captured in 2015-2016, using odour-baited Nzi traps (16) 126 deployed at sites in Grumeti and Ikorongo wildlife reserve, and Serengeti National Park of Tanzania. 127 Captured flies were stored individually in 100% ethanol at room temperature and returned to LSTM 128 for analysis. DNA extraction was carried out using Genejet DNA purification kit (Thermo K0721) 129 according to the manufacturer's instructions. Flies were screened using TBR PCR (9) to identify those 130 infected with T. brucei s. I parasites. All T. brucei s. I positive flies were screened for the presence of 131 human pathogenic trypanosomes using the multiplexed HRM. Samples were classified as positive by 132 the presence of a peak occurring at the predicted Tm with a height above 10% of the maximum dF/dT of the highest peak. Confirmatory testing was done by processing all flies using SRA PCR for T. 133 134 b. rhodesiense (10) and TgsGP PCR for T. b. gambiense (15). Two of the 96 samples were previously

- identified as being *T. b. rhodesiense* using SRA PCR. Further details of the collection, DNA extraction
- and analyses of the tsetse are reported by Lord *et al* (16).
- 137 Results
- 138 One pair of primers per target was selected based on amplification, distinct Tm and peak
- 139 fluorescence. Product sizes for each amplicon ranged from 134-319 base pairs (Table 1) with peak
- temperatures ranging from 79.2°C to 87.5°C.To allow for automated calling of peaks, bin widths of
- 141 1.5°C (0.75°C either side of diagnostic Tm) were set for each target.
- 142 Table 1 Primers included in the HRM multiplex

Primer	Species	Primer sequence 5'-3'	Primer GC	Product	Reference
			(%)	size (bp)	
TbRh1	Т. b.	GAAGCGGAAGCAAGAATGAC	50	134	This study
TbRh2	rhodesiense	GGCGCAAGACTTGTAAGAGC	55		
TgsGP1	Т. b.	GCTGCTGTGTTCGGAGAGC	63	308	(15)
TGsGP2	gambiense	GCCATCGTGCTTGCCGCTC	68		
GPI-PLC1	Trypanozoon	CAGTGTTGCGCTTAAATCCA	45	319	This study
GPI-PLC2		CCCGCCAATACTGACATCTT	50		

- 143 Analytical specificity and sensitivity
- 144 No non-specific amplification was seen when the assay was challenged with a range of non-target
- 145 trypanosome species, namely T. congolense (Savannah, Kilifi and Forest subgroups), T. vivax, T.
- simiae, T. simiae Tsavo, T. godfreyi and T. grayi. The limit of detection was found to be 10⁴
- 147 trypanosomes/mL for *T. b. gambiense* and *T. b. rhodesiense* using purified DNA. When the analytical
- sensitivity of the HRM was compared to TgsGP and SRA PCR, the HRM was as sensitive at detecting
- 149 *T. b. gambiense* and tenfold more sensitive for *T. b. rhodesiense*.


150 Screening of field samples

- 151 GPI-PLC positive control peaks were produced by 43 samples (45%), indicating sufficient DNA
- 152 quantity for species specific gene detection (Table 2). Of these 43 flies, three were identified as
- 153 positive for *T. b. rhodesiense* DNA (Error! Reference source not found.). No samples were positive
- 154 for *T. b. gambiense*. The HRM results were consistent with those produced by SRA and TgsGP PCR.
- 155 Flies that were positive for GPI-PLC but negative for *T. b. gambiense* or *T. b. rhodesiense* were
- 156 considered to be infected with livestock trypanosome *T. b. brucei*.

157 Table 2 Number of positive flies for T. b. gambiense, T. b. rhodesiense and GPI-PLC

	Positive samples	
Target	HRM (n)	PCR (n)
T. b. gambiense	0	0
T. b. rhodesiense	3	3
GPI-PLC	43	19

158 Figure 1 Melt profile of field samples showing three T. b. rhodesiense positives



159 Discussion

Here we describe a novel high-resolution melt analysis for the detection and differentiation of *T. b. rhodesiense* and *T. b. gambiense*. This multiplexed assay screens for both pathogenic trypanosome species simultaneously with the addition of a third primer set to identify the presence of sufficient DNA to detect single-copy genes, acting as a positive control. The assay demonstrated high specificity with no cross-reaction with other non-target trypanosome species also transmitted by tsetse. The limit

165 of detection of the HRM was lower than those reported in the literature for TgsGP (15) and SRA PCR 166 (10). However, when the three assays were tested on a dilution series of DNA, HRM was found to be 167 as sensitive as TgsGP PCR and 10-fold more sensitive than SRA PCR. The assay correctly identified three 168 wild caught tsetse flies to be positive for T. b. rhodesiense DNA. These data were in agreement with 169 reference sub-species PCRs. Of the 96 flies screened, 45% were found to have adequate genetic 170 material for single-copy gene detection. As a result, 55% of tsetse remained unidentified to sub-171 species level. The method has three advantages over traditional PCR methods. First, the HRM time to 172 result of ≤ 2 hours is faster than PCR followed by gel electrophoresis which can take over ≥ 3 hours for 173 product amplification and visualisation. Second, this is a closed-tube assay which reduces 174 contamination risk. Finally, it does not require interpretation of gel electrophoresis results. Through 175 the use of detection bins, sample processing can also be automated, further speeding up and 176 simplifying data analysis. The simple and fast nature of this method indicates it could be suitable for 177 the high-throughput processing of tsetse. With prevalence of *T. b. gambiense* in tsetse from HAT foci 178 predicted to be as low as 1 in 10^5 (17), there is a need for a xenomonitoring tool which can be applied 179 to large numbers of samples. With further optimisation of the assay and DNA extraction protocol, our 180 method could be applied in the remote and low-resource settings typical of most HAT cases. This 181 method could therefore provide the basis of a real-time trypanosome transmission monitoring 182 platform, enabling timely reactive measures by disease control programmes. Furthermore, with the 183 traditionally distinct geographical distributions of both Rhodesian and Gambian HAT changing due to 184 the movement of livestock (18), human migration (19) and climate change (20–23), it may become 185 increasingly important to simultaneously screen for both trypanosome species. The HRM allows for 186 this and removes the risk of presumptive screening based on historic disease distributions.

187 The authors acknowledge that the reliance of low copy genes for target identification is a limiting 188 factor of the described diagnostic assay. However, at present these single copy genes are the only 189 identifiers of members of the *T. brucei s. I* and so poses a challenge to any diagnostic method based 190 on these targets. This study was also challenged by the unavailability of any field-caught *T. b.*

191	gambiense infected tsetse flies. As previously mentioned, trypanosome prevalence in HAT foci is		
192	predicted to be very low (17), therefore making obtaining sufficient field samples for assay validation		
193	an ongoing challenge.		
194	In summary, we describe the development of a novel HRM assay for the detection and		
195	discrimination of human African trypanosomes in tsetse flies. The assay also incorporates an internal		
196	control, identifying samples with sufficient genomic material. The closed tube nature of the assay in		
197	addition to the relatively fast time to result lends itself to use in high-throughput xenomonitoring		
198	surveillance campaigns for HAT.		
199	Acknowledgments		
200	We thank Drs Liam Morrison and Jennifer Lord for providing the Tanzanian tsetse samples and		
201	screening data collected under the auspices of the Zoonosis and Emerging and Livestock Systems		
202	(ZELS) programme (BB/L019035/1).		
203	References		
204	1.	World Health Organization. Trypanosomiasis, human African (sleeping sickness) [Internet].	
205		[cited 2018 Sep 6]. Available from: http://www.who.int/news-room/fact-	
206		sheets/detail/trypanosomiasis-human-african-(sleeping-sickness)	
207	2.	World Health Organization. Accelerating work to overcome the global impact of neglected	
208		tropical diseases: a roadmap for implementation: executive summary. 2012;	
209	3.	World Health Organization. Control and surveillance of human African trypanosomiasis. [cited	
210		2018 Jun 18]; Available from:	
211		http://apps.who.int/iris/bitstream/handle/10665/95732/9789241209847_eng.pdf?sequence	
212		=1&isAllowed=y	
213	4.	Tong J, Valverde O, Mahoudeau C, Yun O, Chappuis F. Challenges of controlling sleeping	

214		sickness in areas of violent conflict: experience in the Democratic Republic of Congo. Confl
215		Health [Internet]. BioMed Central; 2011 Dec 26 [cited 2019 Sep 12];5(1):7. Available from:
216		https://conflictandhealth.biomedcentral.com/articles/10.1186/1752-1505-5-7
217	5.	Keating J, Yukich JO, Sutherland CS, Woods G, Tediosi F. Human African trypanosomiasis
218		prevention, treatment and control costs: A systematic review. Vol. 150, Acta Tropica. Elsevier
219		B.V.; 2015. p. 4–13.
220	6.	Farid HA, Morsy ZS, Helmy H, Ramzy RMR, El Setouhy M, Weil GJ. A critical appraisal of
221		molecular xenomonitoring as a tool for assessing progress toward elimination of lymphatic
222		filariasis. Am J Trop Med Hyg. 2007 Oct;77(4):593–600.
223	7.	Schmaedick MA, Koppel AL, Pilotte N, Torres M, Williams SA, Dobson SL, et al. Molecular
224		Xenomonitoring Using Mosquitoes to Map Lymphatic Filariasis after Mass Drug
225		Administration in American Samoa. Bockarie M, editor. PLoS Negl Trop Dis [Internet]. 2014
226		Aug 14 [cited 2020 Jan 15];8(8):e3087. Available from:
227		https://dx.plos.org/10.1371/journal.pntd.0003087
228	8.	Lau CL, Won KY, Lammie PJ, Graves PM. Lymphatic Filariasis Elimination in American Samoa:
229		Evaluation of Molecular Xenomonitoring as a Surveillance Tool in the Endgame. Rinaldi G,
230		editor. PLoS Negl Trop Dis [Internet]. 2016 Nov 1 [cited 2020 Jan 15];10(11):e0005108.
231		Available from: https://dx.plos.org/10.1371/journal.pntd.0005108
232	9.	Moser DR, Ochs DE, Bailey CP, McKane MR, Donelson JE, Cook GA. Detection of trypanosoma
233		congolense and trypanosoma brucei subspecies by dna amplification using the polymerase
234		chain reaction. Parasitology [Internet]. 1989 Aug 6 [cited 2020 Feb 12];99(1):57–66. Available
235		from:
236		https://www.cambridge.org/core/product/identifier/S0031182000061023/type/journal_artic
237		le

238	10.	Picozzi K, Carrington M, Welburn SC. A multiplex PCR that discriminates between
239		Trypanosoma brucei brucei and zoonotic T. b. rhodesiense. Exp Parasitol. 2008
240		Jan;118(1):41–6.
241	11.	Hereld D, Hart GW, Englund PT. cDNA encoding the glycosyl-phosphatidylinositol-specific
242		phospholipase C of Trypanosoma brucei (glycolipid anchor/variant surface glycoprotein). Vol.
243		85, Proc. Natl. Acad. Sci. USA. 1988.
244	12.	Carrington M, Bülow R, Reinke H, Overath P. Sequence and expression of the glycosyl-
245		phosphatidylinositol-specific phospholipase C of Trypanosoma brucei. Mol Biochem Parasitol.
246		Elsevier; 1989 Mar 15;33(3):289–96.
247	13.	Winkle S. Geißeln der Menschheit. Kulturgeschichte der Seuchen. Kult der Seuchen.
248		1997; Düsseldorf.
249	14.	Mensa Wilmot K, Hereld D, Englund PT. Genomic Organization, Chromosomal Localization,
250		and Developmentally Regulated Expression of the Glycosyl-Phosphatidylinositol-Specific
251		Phospholipase C of Trypanosoma brucei [Internet]. MOLECULAR AND CELLULAR BIOLOGY.
252		1990 [cited 2020 Feb 17]. Available from: http://mcb.asm.org/
253	15.	Radwanska M, Claes F, Magez S, Magnus E, Pérez-Morga D, Pays E, et al. Novel primer
254		sequences for Polymerase Chain Reaction-based detection of [Internet]. 2014 [cited 2018 Sep
255		10]. Available from: https://www.researchgate.net/publication/11055435
256	16.	JS Lord, RS. Lea, FK. Allan, M Byamungu, DR Hall, J Lingley, F Mramba, E Paxton, GA Vale, JW
257		Hargrove, LJ Morrison, SJ Torr HA. Assessing the effect of insecticide-treated cattle on tsetse
258		abundance and trypanosome transmission at the wildlife-livestock interface in Serengeti,
259		Tanzania. bioRxiv doi. 2020;
260	17.	Rock KS, Torr SJ, Lumbala C, Keeling MJ. Quantitative evaluation of the strategy to eliminate
261		human African trypanosomiasis in the Democratic Republic of Congo. Parasites and Vectors.

262 BioMed Central Ltd.; 2015 Oct 22;8(1):1–13.

263	18.	Selby R, Bardosh K, Picozzi K, Waiswa C, Welburn SC. Cattle movements and trypanosomes:
264		restocking efforts and the spread of Trypanosoma brucei rhodesiense sleeping sickness in
265		post-conflict Uganda. Parasit Vectors [Internet]. BioMed Central; 2013 Sep 27 [cited 2019 Sep
266		12];6(1):281. Available from:
267		http://parasitesandvectors.biomedcentral.com/articles/10.1186/1756-3305-6-281
268	19.	Picado A, Ndung'u J. Elimination of sleeping sickness in Uganda could be jeopardised by
269		conflict in South Sudan. Vol. 5, The Lancet Global Health. Elsevier Ltd; 2017. p. e28–9.
270	20.	Lord JS, Hargrove JW, Torr SJ, Vale GA. Climate change and African trypanosomiasis vector
271		populations in Zimbabwe's Zambezi Valley: A mathematical modelling study. Thomson M,
272		editor. PLOS Med [Internet]. Public Library of Science; 2018 Oct 22 [cited 2020 Feb
273		18];15(10):e1002675. Available from: http://dx.plos.org/10.1371/journal.pmed.1002675
274	21.	Moore S, Shrestha S, Tomlinson KW, Vuong H. Predicting the effect of climate change on
275		African trypanosomiasis: integrating epidemiology with parasite and vector biology. [cited
276		2020 Feb 18]; Available from: http://rsif.royalsocietypublishing.org.
277	22.	Fèvre EM, Coleman PG, Odiit M, Magona JW, Welburn SC, Woolhouse MEJ. The origins of a
278		new Trypanosoma brucei rhodesiense sleeping sickness outbreak in eastern Uganda. Lancet
279		[Internet]. Elsevier Limited; 2001 Aug 25 [cited 2020 Feb 17];358(9282):625–8. Available
280		from: https://linkinghub.elsevier.com/retrieve/pii/S0140673601057786
281	23.	Picozzi K, Fèvre EM, Odiit M, Carrington M, Eisler MC, Maudlin I, et al. Sleeping sickness in
282		Uganda: a thin line between two fatal diseases. 2001 [cited 2020 Feb 17]; Available from:
283		http://www.bmj.com/
284		